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166letter to editorFigure 1. Bilateral cutaneous ulceration over the plantar aspect of the soles after five years of
HU therapy.Successful treatment
of hydroxyurea-associ
ated chronic leg ulcers
associated with
squamous cell carcinoma
Hydroxyurea (HU) is an anti-
neoplastic drug used in the treat-
ment of chronic
myeloproliferative neoplasms
(MPNs). HU is associated with
cutaneous adverse effects, whereas
severe complications such as leg
ulcers and non-melanoma skin
cancers (NMSCs) are rare and
only observed after long-term
treatment. We herein report a
patient with essential thrombocy-
themia (ET) treated chronically
with HU, and who developed
refractory bilateral leg ulcers com-
plicated by squamous cell carci-
noma (SCC) over both heels.
The patient was successfully man-
aged by multiple debridement
stages and skin grafting surgeries.
HU is generally used to treat
myeloproliferative disorders, par-
ticularly essential thrombocythe-
mia (ET) and polycythemia vera
(PV). 1,2 Common cutaneous side
effects include xerosis, hyperpig-
mentation of the skin folds and
nails, alopecia, scaling, skin atro-
phy, lichen-planus and dermato-
myositis-like eruptions. In
addition, rare and more severe
cutaneous manifestations, such as
non-healing leg ulcers and cutane-
ous malignancies have been
reported in a few studies and case
reports.3–5 Chronic non-healing
ulcers are at increased risk of har-
boring squamous cell carcinoma
(SCC).6 Several cases of HU-
related cutaneous SCCs have been
reported.3,7–14 The synergistic
action of long-term HU and ultra-
violet (UV) light exposures arestrongly implicated in the develop-
ment of cutaneous SCC.15 This
report demonstrates a successful
multidisciplinary management of
HU-induced bilateral chronic leg
ulcers associated with SCC.CASE PRESENTATION
A 60-year-old Caucasian woman
presented to our clinic for evalua-
tion of thrombocytosis
(900 · 109/L) that was inciden-
tally discovered after suffering a
myocardial infarction. Bone
marrow evaluation revealed hyper-
cellularity with increased megakar-
yocytes. The patient had diploid
karyotype, and molecular analysis
revealed JAK2 V617F mutation
with no BCR–ABL fusion gene.
The diagnosis of ET was made
based on the World Health Orga-Hematolnization (WHO) 2008 criteria.
She was started on low dose aspi-
rin and HU.
In the ﬁfth year of HU treat-
ment, she developed painful ery-
thematous, ulcerated plaques over
the plantar aspect of bilateral feet
(Fig. 1). HU was discontinued
and she was switched to anagre-
lide. However, she was unable to
tolerate it and was shifted to
peginterferon a-2a (Pegasys)
with subsequent improvement.
Nevertheless, the leg ulcers did
not heal completely after HU dis-
continuation. Three years later,
the patient developed painful ﬂe-
shy erythematous papules within
the heel ulcers. A punch biopsy
revealed an inﬁltrating and kerati-
nizing SCC with focal areas of
SCC in-situ (Bowen’s disease).
Bilateral surgical excision revealedOncol Stem Cell Ther 7(4) Fourth Quarter 2014
Figure 2. (A and B) Invasive moderately-differentiated keratinizing SCC involving the dermis, with an associated ulcer (mag 40·). (C and D) Areas
of SCC in-situ (Bowen's disease) (mag 100· and 400·).
Figure 3. Complete resolution of skin lesions after three surgical debridement and skin grafting surgeries.
letter to editorthe same pathologic changes
(Fig. 2). After one surgical
debridement and two grafting pro-
cedures, the patient had complete
resolution of the lesions, and no
recurrence with three years of fol-
low-up (Fig. 3).DISCUSSION
HU is the approved ﬁrst-line ther-
apy for patients with high risk ET
and PV.1,2,16 Only ten case reportsHematol Oncol Stem Cell Ther 7(4) Fourth Quarter 20in the literature illustrate an asso-
ciation between long-term HU
therapy and SCC in Ph-negative
MPNs patients (Table 1). Among
them, only one case described a
chronic leg ulcer with malignant
degeneration into SCC.11
Discontinuation of HU is the
cornerstone of treatment of HU-
related ulcers. Dermatologic exam-
ination should be emphasized dur-
ing long-term HU therapy. This
report highlights the importance14of repeated skin ulcer biopsies in
patients on HU, especially if the
ulcers persist despite HU discon-
tinuation. This early intervention
is crucial for the early diagnosis
of skin cancer and for prompt
management. Furthermore, any
diagnosed skin cancer should be
addressed by a multidisciplinary
team approach.167
Table 1. Hydroxyurea related skin squamous cell carcinoma in Ph-negative MPNs patients.
Authors No. of
cases
Disease Age/sex HU dose HU duration Description of skin SCC Other HU related toxicity Treatment Outcome
Saraceno
et al.7
1 PMF 81/M 1 g/d 6 months Multiple face and extremities
skin SCC
– Actinic keratoses
– Keratoacanthomas
– Nail changes
– Imiquimod cream 5%
– HU was not stopped
– CR of skin SCC
– Nail unchanged
– New skin lesions
Hoff et al.8 1 PV 86/F n/a 8 years SCC in the lower leg – Actinic keratoses
– Painful ulcers
– HU was stopped
– Cryotherapy for keratoses
– Excision for SCC
– CR of skin SCC and actinic
keratoses
Schleubinger
et al.9
1 ET 80/F 750 mg/d 13 years Multiple SCC of the face – Multiple large
– Hyperkeratoses
n/a n/a
Zaccaria
et al.10
1 ET 73/M 1 g/d 12 years Five SCC of the face – Dermatomyositis-like eruption together
with a leg ulceration
– Poikilodermatouskeratotic lesions
– HU was stopped
– Excision of face SCC
– Busulfan 8 mg/day
– Resolution of all skin lesions
after 3 month of HU
withdrawal
Stone et al.11 1 PV 62/F n/a 9 years Left heel SCC on top of non
healing ulcer
– Non healing ulcer of the left heel
– Face basal cell carcinoma
– HU was stopped
– Multiple surgical
debridement
Complete healing of the wound
after multidisciplinary treatment
Callot-Mellot
et al.3
2 1-ET 2-
PV
1–64/M
2–69/F
Cumulative doses
between 650 and
3600 g
1–5.5 years
2–8.5 years
1–3 skin SCC 2- In situ SCC
on dorsal face of a finger
1- Xerosis, melanonychia, actinic
keratosis.
2- Hyperpigmentation, keratoderma,
erythema, actinic keratosis
1- Surgical excision and
discontinuation of HU
2- Surgical excision with-
out discontinuation of
HU
1- No recurrence after
3 years follow up
2- No recurrence
Salmon-Ehr
et al.12
1 PV 73/M n/a 10 years One ear SCC Multiple actinic keratosis HU was stopped Surgical
excision Busulfan was
introduced
– No recurrence Clearance of
actinic
– Keratosis 14 months after HU
discontinuation
Best and
Pettit
et al.13
1 ET 59/F n/a 8 years 4 face SCC Multiple actinic keratosisLichen planus like
lesionsMultiple basal cell carcinoma
HU was stopped Anagrelide
was introduced
Improvement after HU
discontinuation
Esteve et al.14 1 PV 83/F 1 g/day 13 years 7 skin SCC – Oral SCC
– Xerosis
– Atrophic erythematous lesions and
ulcers on hands
HU was stopped New SCC despite HU
discontinuation
PMF, primary myelofibrosis; SCC, squamous cell carcinoma; ET, essential thrombocythemia; PV, polycythemia vera; CR, complete remission; HU, hydroxyurea.
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